Design, synthesis and bioactivity evaluation of novel N-phenyl-substituted evodiamine derivatives as potent anti-tumor agents. 2022

Xiangyong Hao, and Jiedan Deng, and Honghua Zhang, and Ziyi Liang, and Fang Lei, and Yuqing Wang, and Xiaoyan Yang, and Zhen Wang
Department of General Surgery, Gansu Provincial Hospital, Lanzhou 730000, China.

Natural products are important sources for the development of therapeutic medicine, among which evodia fruit has a wide range of medicinal properties in traditional Chinese medicine. Evodiamine, the main active component of evodia fruit, has various anti-cancer effects and has been proved to be a Topo inhibitor. From our previous attempts of modifying evodiamine, we found that the N14 phenyl substituted derivatives had showed great anti-tumor activity, which prompted us to further explore the novel structures and activities of these compounds. Compound 6f, as a N14 3-fluorinated phenyl substituted evodiamine derivative, showed a certain inhibitory activity against Topo I at 200 μM. By studying its anti-tumor effects in vitro, compound 6f could inhibit proliferation and induce apoptosis, as well as arrest the cell cycle of HGC-27 and HT-29 cell lines at G2/M phase in a concentration-dependent manner. Moreover, compound 6f could inhibit the migration and invasion of HGC-27 cell lines. Meanwhile, compound 6f could induce apoptosis of HGC-27 cells by inhibiting PI3K/AKT pathway. Overall, this work demonstrated that the N14 phenyl-substituted evodiamine derivatives had a good inhibitory effect on tumor cells in vitro, providing a promising strategy for developing potential anticancer agents for the treatment of gastrointestinal tumors.

UI MeSH Term Description Entries

Related Publications

Xiangyong Hao, and Jiedan Deng, and Honghua Zhang, and Ziyi Liang, and Fang Lei, and Yuqing Wang, and Xiaoyan Yang, and Zhen Wang
September 2022, Bioorganic chemistry,
Xiangyong Hao, and Jiedan Deng, and Honghua Zhang, and Ziyi Liang, and Fang Lei, and Yuqing Wang, and Xiaoyan Yang, and Zhen Wang
January 2019, Anti-cancer agents in medicinal chemistry,
Xiangyong Hao, and Jiedan Deng, and Honghua Zhang, and Ziyi Liang, and Fang Lei, and Yuqing Wang, and Xiaoyan Yang, and Zhen Wang
August 2023, Chemistry & biodiversity,
Xiangyong Hao, and Jiedan Deng, and Honghua Zhang, and Ziyi Liang, and Fang Lei, and Yuqing Wang, and Xiaoyan Yang, and Zhen Wang
June 2024, ChemMedChem,
Xiangyong Hao, and Jiedan Deng, and Honghua Zhang, and Ziyi Liang, and Fang Lei, and Yuqing Wang, and Xiaoyan Yang, and Zhen Wang
July 2023, European journal of medicinal chemistry,
Xiangyong Hao, and Jiedan Deng, and Honghua Zhang, and Ziyi Liang, and Fang Lei, and Yuqing Wang, and Xiaoyan Yang, and Zhen Wang
June 2022, Journal of medicinal chemistry,
Xiangyong Hao, and Jiedan Deng, and Honghua Zhang, and Ziyi Liang, and Fang Lei, and Yuqing Wang, and Xiaoyan Yang, and Zhen Wang
April 2014, International journal of molecular sciences,
Xiangyong Hao, and Jiedan Deng, and Honghua Zhang, and Ziyi Liang, and Fang Lei, and Yuqing Wang, and Xiaoyan Yang, and Zhen Wang
January 2016, Anti-inflammatory & anti-allergy agents in medicinal chemistry,
Xiangyong Hao, and Jiedan Deng, and Honghua Zhang, and Ziyi Liang, and Fang Lei, and Yuqing Wang, and Xiaoyan Yang, and Zhen Wang
June 2018, Bioorganic & medicinal chemistry letters,
Xiangyong Hao, and Jiedan Deng, and Honghua Zhang, and Ziyi Liang, and Fang Lei, and Yuqing Wang, and Xiaoyan Yang, and Zhen Wang
November 2015, European journal of medicinal chemistry,
Copied contents to your clipboard!